News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,886 Results
Type
Article (51460)
Company Profile (281)
Press Release (691145)
Section
Business (213810)
Career Advice (2135)
Deals (36821)
Drug Delivery (109)
Drug Development (87747)
Employer Resources (173)
FDA (17141)
Job Trends (15820)
News (364932)
Policy (35047)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2804)
Accelerated approval (4)
Adcomms (27)
Allergies (87)
Alliances (52067)
ALS (92)
Alzheimer's disease (1450)
Antibody-drug conjugate (ADC) (129)
Approvals (17116)
Artificial intelligence (260)
Autoimmune disease (21)
Automation (14)
Bankruptcy (379)
Best Places to Work (12153)
BIOSECURE Act (18)
Biosimilars (108)
Biotechnology (192)
Bladder cancer (64)
Brain cancer (29)
Breast cancer (270)
Cancer (2136)
Cardiovascular disease (186)
Career advice (1784)
Career pathing (30)
CAR-T (152)
Cell therapy (419)
Cervical cancer (21)
Clinical research (71273)
Collaboration (815)
Compensation (475)
Complete response letters (28)
COVID-19 (2777)
CRISPR (40)
C-suite (225)
Cystic fibrosis (102)
Data (2032)
Decentralized trials (2)
Denatured (26)
Depression (50)
Diabetes (268)
Diagnostics (6581)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (115)
Drug pricing (104)
Drug shortages (28)
Duchenne muscular dystrophy (93)
Earnings (88859)
Editorial (36)
Employer branding (21)
Employer resources (147)
Events (117990)
Executive appointments (671)
FDA (18310)
Featured Employer (49)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (727)
Gene editing (107)
Generative AI (24)
Gene therapy (303)
GLP-1 (783)
Government (4705)
Grass and pollen (5)
Guidances (49)
Healthcare (19990)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (27)
Infectious disease (2922)
Inflammatory bowel disease (145)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (88)
Interviews (329)
IPO (16974)
IRA (41)
Job creations (4100)
Job search strategy (1523)
Kidney cancer (10)
Labor market (34)
Layoffs (504)
Leadership (16)
Legal (8499)
Liver cancer (73)
Lung cancer (317)
Lymphoma (138)
Machine learning (4)
Management (58)
Manufacturing (279)
MASH (67)
Medical device (14341)
Medtech (14346)
Mergers & acquisitions (20330)
Metabolic disorders (703)
Multiple sclerosis (79)
NASH (22)
Neurodegenerative disease (101)
Neuropsychiatric disorders (30)
Neuroscience (1986)
NextGen: Class of 2025 (6955)
Non-profit (4748)
Northern California (2485)
Now hiring (37)
Obesity (384)
Opinion (226)
Ovarian cancer (75)
Pain (90)
Pancreatic cancer (78)
Parkinson's disease (146)
Partnered (20)
Patents (210)
Patient recruitment (101)
Peanut (51)
People (60314)
Pharmaceutical (70)
Pharmacy benefit managers (19)
Phase I (22126)
Phase II (31307)
Phase III (23477)
Pipeline (1100)
Podcasts (72)
Policy (117)
Postmarket research (2810)
Preclinical (9077)
Press Release (68)
Prostate cancer (99)
Psychedelics (37)
Radiopharmaceuticals (258)
Rare diseases (393)
Real estate (6356)
Recruiting (65)
Regulatory (23942)
Reports (46)
Research institute (2516)
Resumes & cover letters (364)
Rett syndrome (4)
RNA editing (4)
RSV (45)
Schizophrenia (74)
Series A (126)
Series B (84)
Service/supplier (13)
Sickle cell disease (55)
Southern California (2158)
Special edition (15)
Spinal muscular atrophy (157)
Sponsored (30)
Startups (3869)
State (2)
Stomach cancer (16)
Supply chain (65)
Tariffs (11)
The Weekly (44)
United States (21977)
Vaccines (735)
Venture capitalists (39)
Webinars (12)
Weight loss (272)
Women's health (36)
Worklife (15)
Date
Today (104)
Last 7 days (685)
Last 30 days (2757)
Last 365 days (34793)
2025 (8624)
2024 (36580)
2023 (41568)
2022 (52858)
2021 (57519)
2020 (56227)
2019 (49121)
2018 (37219)
2017 (34235)
2016 (34014)
2015 (39952)
2014 (33857)
2013 (29048)
2012 (31255)
2011 (32022)
2010 (30449)
Location
Africa (806)
Alabama (50)
Alaska (7)
Arizona (234)
Arkansas (14)
Asia (41866)
Australia (7004)
California (5682)
Canada (1900)
China (499)
Colorado (259)
Connecticut (274)
Delaware (132)
Europe (91625)
Florida (847)
Georgia (205)
Idaho (61)
Illinois (542)
India (24)
Indiana (301)
Iowa (9)
Japan (144)
Kansas (104)
Kentucky (24)
Louisiana (9)
Maine (61)
Maryland (877)
Massachusetts (4315)
Michigan (215)
Minnesota (386)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (58)
New Hampshire (68)
New Jersey (1630)
New Mexico (29)
New York (1637)
North Carolina (1008)
North Dakota (7)
Northern California (2485)
Ohio (194)
Oklahoma (14)
Oregon (36)
Pennsylvania (1279)
Puerto Rico (10)
Rhode Island (29)
South America (1192)
South Carolina (19)
South Dakota (1)
Southern California (2158)
Tennessee (97)
Texas (853)
Utah (170)
Virginia (136)
Washington D.C. (61)
Washington State (536)
West Virginia (3)
Wisconsin (50)
742,886 Results for "phase iii medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
·
1 min read
·
Dan Samorodnitsky
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Phase III
Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up
against its limits
after racking up around 50 approvals since getting its first FDA nod in September 2014.
January 24, 2025
·
2 min read
·
Annalee Armstrong
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
·
1 min read
·
Kate Goodwin
Obesity
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s prior projections for the therapy. Meanwhile, Eli Lilly’s stock rose on the news.
December 20, 2024
·
3 min read
·
Tristan Manalac
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data
The discontinuation caps off a turbulent development path for izokibep, which in September 2023 produced disappointing results from Phase IIb/III study in hidradenitis suppurativa that was found to have had dosing errors.
December 11, 2024
·
2 min read
·
Tristan Manalac
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.
March 31, 2025
·
4 min read
·
Annalee Armstrong
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
1 of 74,289
Next
